This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial intelligence-based quantitative coronary computed tomography (AI-QCT) conferred a higher relative risk of major adverse cardiovascular events (MACE) in women, based on findings from the CONFIRM II trial presented at ACC.25 in Chicago and simultaneously published in Circulation: Cardiovascular Imaging.
In the continuously evolving world of healthcare, keeping up with the latest findings, technologies, and best practices is vital for medical professionals. One of the most effective ways to do this is through conferences that focus on medical education. These events are not just a way to earn continuing education credits; they are foundational to shaping how healthcare providers learn and apply knowledge in their practices.
AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background moderate- or high-intensity statin treatment, according to research presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC.
(MedPage Today) -- This story was originally published by ProPublica. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox. Although it was too late.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Angiopoietin-like 3 (ANGPTL-3) inhibition with the human monoclonal antibody, SHR-1918, reduces serum LDL-C by 22% to 30%, as well as triglyceride (TG) levels by 52% to 63%, in patients at moderate or higher risk of atherosclerotic cardiovascular disease (ASCVD), with the effect being dose and frequency dependent, according to research presented during a Clinical and Investigative Horizons session at ACC.25 in Chicago and simultaneously published in JACC.
tim.hodson Mon, 03/31/2025 - 16:38 March 29, 2025 Anthos Therapeutics, Inc., presented two new analyses from itsAZALEA-TIMI 71 study at the American College of Cardiology Annual Scientific Session (ACC.25) demonstrating the novel Factor XI inhibitor abelacimab significantly reduced bleeding in patients regardless of age or bleeding risk. In the first analysis, the safety of abelacimab, a novel Factor XI inhibitor, was compared to rivaroxaban, a direct oral anticoagulant (DOAC), by patient age.
Among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), the baseline estimated glomerular filtration rate (eGFR) did not impact the effect of tirzepatide on reducing major adverse HF events or to enhance health status, according to a post-hoc analysis of the SUMMIT trial presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC.
Among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), the baseline estimated glomerular filtration rate (eGFR) did not impact the effect of tirzepatide on reducing major adverse HF events or to enhance health status, according to a post-hoc analysis of the SUMMIT trial presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC.
(MedPage Today) -- The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual spending from $1.6 billion to $5.8 billion, survey data showed. Based on an unweighted sample of nearly.
tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes.
New research reveals that lower proportions of specific sleep stages are associated with reduced brain volume in regions vulnerable to the development of Alzheimer's disease over time.
Panelists discuss how systemic treatments for moderate to severe atopic dermatitis offer significant advantages over topicals, including more comprehensive disease control, improved adherence, reduced treatment burden, greater efficacy for widespread disease, ability to address immunological drivers of inflammation, prevention of flares, management of both cutaneous and extracutaneous manifestations, reduced corticosteroid exposure, and potential modification of disease trajectoryparticularly be
Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and prevention of advanced acute coronary syndrome (ACS) has the potential to save 8.7 million lives globally every year, according to a new report from The Lancet Commission presented at ACC.25.
Panelists discuss how the approval of dupilumab and subsequent biologics for moderate to severe atopic dermatitis has fundamentally transformed the treatment landscape by providing targeted, effective options with favorable safety profiles that address underlying disease pathways, shifting from symptomatic management toward long-term disease control, raising expectations for treatment outcomes, reducing reliance on systemic immunosuppressants, enabling personalized therapy based on specific infl
Atrial fibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. Consulting a local cardiologist is crucial for the proper diagnosis and management of AFib.
An estimated 700,000 sternotomies are performed annually in the United States. It is a serious surgery that opens up the chest cavity through the breastbone, or sternum, to gain access to the lungs and heart.
(MedPage Today) -- Three days of intermittent fasting (IMF) each week was a bit better for weight loss than daily caloric restriction (DCR), the DRIFT randomized trial found. Over 12 months, participants who restricted their energy intake by 80.
(MedPage Today) -- CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared with placebo from.
Despite failing to achieve significance for its primary endpoint, investigators suggest the trial further demonstrates the potential of cell therapy in HFrEF.
A trial of 648 patients found that the new automated method and intervention strategy resulted in nearly four times as many diagnoses and treatment plans for high blood pressure compared with traditional office-based health care visits.
Having a coronary artery calcium (CAC) score of zero has generally been accepted as a marker of a very low risk of having a cardiac event within the next five years. However, age is a strong contributor to coronary risk, with risk increasing markedly as people age.
Stroke, Ahead of Print. BACKGROUND:Tissue-level hypoperfusion (no-reflow) persists in 30% of patients with seemingly successful upstream angiographic recanalization at thrombectomy. We investigated the clinical impact of the no-reflow phenomenon by comparing patients with no-reflow versus patients with varying degrees of angiographic recanalization.METHODS:In a post hoc pooled analysis of the EXTEND-IA (Endovascular Therapy for Ischemic Stroke With Perfusion-Imaging Selection) and EXTEND-IA TNK
It is my great honor to serve this wonderful community as your 76th president. I would like to start by congratulating all of you who are receiving your FACC and AACC designations today.
(MedPage Today) -- Prenatal use of smoking cessation therapies was not linked to increased risks of major congenital malformations (MCMs) compared with smoking during the first trimester, a retrospective cohort study suggested. Compared with unexposed.
(MedPage Today) -- Scientists have developed a device that can translate thoughts about speech into spoken words in real time. Although it's still experimental, they hope the brain-computer interface could someday help give voice to those unable.
The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.
The goal of the Altshock-2 trial was to evaluate the effect of early intra-aortic balloon pump (IABP) use vs. standard care on 60-day survival or successful bridging to heart replacement therapies (HRT) in patients with heart failurecardiogenic shock (HF-CS).
Solbinsiran at the 400 mg dose reduced apolipoprotein B (apoB) concentration in patients with mixed dyslipidemia, according to research presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in The Lancet.
The latest science coming out of ACC.25, held March 29-31 in Chicago, IL, illuminated new approaches in how artificial intelligence (AI) can be used to improve the efficiency of cardiovascular care, expand the reach into underserved communities and more.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
65 
Let's personalize your content